Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View item
  • Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-01
ICR Author
Lalondrelle, Susan
Marsden,
Author
Fife, K
Herd, R
Lalondrelle, S
Plummer, R
Strong, A
Jones, S
Lear, JT
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Basal cell carcinomas are the most common form of skin cancer. Some develop into advanced cases not suitable for standard therapy. Vismodegib is the first-in-class oral hedgehog pathway inhibitor (which is dysregulated in 90% of basal cell carcinomas), and has demonstrated efficacy for advanced disease in clinical trials. An UK expert panel met to discuss management strategies for adverse events associated with vismodegib (most commonly taste disturbances, muscle cramps and alopecia). Managing patient expectations and implementing treatment breaks were considered important strategies. Quinine was useful to alleviate muscle cramps. For taste disturbances, food swaps alongside dietician referral were suggested. The experts concluded that these common adverse events can be successfully managed to allow optimum treatment duration of vismodegib.
URI
https://repository.icr.ac.uk/handle/internal/1313
DOI
https://doi.org/10.2217/fon-2016-0296
Collections
  • Radiotherapy and Imaging
Subject
Humans
Carcinoma, Basal Cell
Skin Neoplasms
Anilides
Pyridines
Antineoplastic Agents
Disease Management
Clinical Trials as Topic
Drug-Related Side Effects and Adverse Reactions
Research team
Gynaecological Cancer
Language
eng
License start date
2017-01
Citation
Future oncology (London, England), 2017, 13 (2), pp. 175 - 184

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.